

APPLICANTS' STATEMENT OF SUBSTANCE OF THE INTERVIEW

Applicants' attorney, Dr. Margaret B. Brivanlou, contacted the Examiner on Thursday, February 7, 2008 to discuss switching the species of marker from that originally elected in the Response to Office Action dated September 25, 2006.

After conferring with her supervisor, the Examiner informed Dr. Brivanlou that such a switch would be possible provided that, with the filing of an RCE, an amendment was filed that withdrew the claims drawn to the currently elected species of marker, *i.e.*, a cytokine (in particular, tumor necrosis factor), and that reinstated the claims directed to the desired species of marker, which is levels and/or amounts of β -amyloid precursor protein or fragments thereof.

The amended claims are presented herewith.